Codexis Opens Singapore Laboratory
Codexis, Inc. announced the opening of Codexis Laboratories Singapore Pte. Ltd. (CLS). CLS is the company's first research facility in Asia, and is an expansion of the company's research and development operations in the U.S. and Europe. CLS will support the company's pharmaceuticals business in both the innovator and generics markets.
"Our expansion to Singapore is a significant part of our global development strategy," Alan Shaw, Ph.D., Codexis President and Chief Executive Officer said. "Singapore offers us access to a highly skilled workforce, proximity to our growing customer base in Asia, and a productive business environment as our company grows. Codexis Laboratories Singapore will play an important role in the development of new products serving our pharmaceuticals markets worldwide."
The 20,000-square foot research and development center is in the Galen, in the Science Park III area of Singapore. When fully staffed, it is expected to house up to 70 R&D and operations personnel.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Parahuman

Powering a microprocessor by photosynthesis - Algae-powered computing: Scientists create reliable and renewable biological photovoltaic cell
Cosmos Alliance - Washington, USA
Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data - Company’s CARE-MS II Phase 3 Trial Completes Enrollment
Safe medications thanks to new test procedures - High-Tech Gründerfonds invests in SIGNATOPE GmbH
Joint efforts to control diseases transmitted from animals to humans - BfR Symposium on Zoonoses and Food Safety
Genmab Announces Lift of Zalutumumab Partial Clinical Hold
Celera and Collaborators Discover a Genetic Marker Associated with Severe Coronary Artery Disease - Carriers of gene variant exhibit an approximate 3-fold increased risk of disease
